COLTENE (CLTN) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
20 Feb, 2026Executive summary
Net sales declined 7.4% year-over-year to CHF 118.1m in H1 2025, mainly due to geopolitical uncertainty, currency headwinds, and temporary order delays from dealer management changes.
EBIT margin dropped to 6.4% from 10.2% in the prior year, reflecting lower sales, market volatility, and operational challenges.
Net profit fell 59.1% to CHF 4.3m, mainly due to lower EBIT and higher FX losses.
Strategic focus remains on efficiency, customer orientation, and innovation, with new product launches and digitisation initiatives underway.
Leadership changes include a new Chairman and former CEO joining the Board.
Financial highlights
Gross profit margin slightly decreased by 0.2pp to 66.4%.
Free cash flow was weak at CHF -0.3m, compared to CHF 13.8m last year, mainly due to higher inventories.
Net debt increased significantly to CHF 34.6m from CHF 18.1m at year-end 2024.
Equity ratio decreased to 51.0% from 58.2% at year-end 2024.
EBITDA margin dropped to 9.2% from 12.9% in H1 2024.
Outlook and guidance
Short-term outlook remains highly volatile due to geopolitical uncertainty and limited visibility.
2025 EBIT margin expected around 10%.
Medium-term (2027) targets: annual sales growth of 3-5% in local currencies, EBIT margin of 13-15%, and payout ratio of about 70%.
Expects positive momentum in H2 2025 as order delays normalize and new products launch.
Latest events from COLTENE
- Net profit fell 27% and EBIT margin dropped to 8.8%, with growth and margin recovery targeted for 2026.CLTN
H2 202513 Mar 2026 - Net sales dipped 3%, but higher margins and new launches support a positive H2 outlook.CLTN
H1 202420 Feb 2026 - Aims for 3–5% annual growth, 13–15% EBIT margin by 2027, and leadership in dental innovation.CLTN
CMD 2024 Presentation20 Feb 2026 - Net profit surged 71% to CHF 20.5m, with EBIT margin up to 10.7% and strong cash flow.CLTN
H2 202420 Feb 2026